Anti-Human CD25 (Camidanlumab) (C1050-GRP)

CD25 is the alpha-chain of the interleukin-2 receptor1, which regulates normal immune function2, and is involved in signal transduction, cell growth and survival1. CD25 is considered an attractive target for conjugated antibody chemotherapeutic development because it is overexpressed in various hematologic malignancies and is associated with poor prognosis. Antibody drug conjugates (ADC) use tumor-associated surface antigens to specifically target cancer cells with cytotoxic agents. Human therapeutic grade Camidanlumab is an ADC composed of a human CD25-directed antibody (HuMax-TAC) that is maleimide- conjugated at reduced interchain cysteines via a cathepsin-cleavable valine-alanine linker to a PBD toxin warhead (SG3199)3. Camidanlumab has a strong binding affinity to CD25-positive human anaplastic large cell lymphoma derived cell lines. This research grade biosimilar has the same specificity as the original therapeutic antibody but lacks the conjugated PBD toxin warhead.